Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern
Time
PHILADELPHIA, June 13,
2024 /PRNewswire/ -- Carisma Therapeutics Inc.
(Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage
biopharmaceutical company focused on discovering and developing
innovative immunotherapies, today announced that the Company's
virtual annual meeting of stockholders held on June 13, 2024 was convened and adjourned, without
any business being conducted, due to technical difficulties with
the third-party hosting site. The meeting will be reconvened at
10:00 a.m. Eastern Time on Friday,
June 14, 2024.
Carisma stockholders will be able to attend the virtual annual
meeting online, vote their shares electronically and submit
questions via the Internet by virtual audio web conference at
https://meetnow.global/MAJJ4AY.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical
company focused on utilizing our proprietary macrophage and
monocyte cell engineering platform to develop transformative
immunotherapies to treat cancer and other serious diseases. We have
created a comprehensive, differentiated proprietary cell therapy
platform focused on engineered macrophages and monocytes, cells
that play a crucial role in both the innate and adaptive immune
response. Carisma is headquartered in Philadelphia, PA. For more information, please
visit www.carismatx.com.
Media Contact:
Julia
Stern
(763) 350-5223
jstern@realchemistry.com
Investors:
Shveta
Dighe
Head of Investor Relations
investors@carismatx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-adjournment-of-annual-meeting-of-stockholders-302172413.html
SOURCE Carisma Therapeutics Inc.
